Egetis Therapeutics AB (publ) (STO: EGTX)
Sweden
· Delayed Price · Currency is SEK
5.34
-0.06 (-1.11%)
Nov 22, 2024, 5:22 PM CET
Egetis Therapeutics AB Revenue
Egetis Therapeutics AB had revenue of 9.40M SEK in the quarter ending September 30, 2024, a decrease of -22.95%. This brings the company's revenue in the last twelve months to 67.90M, up 121.17% year-over-year. In the year 2023, Egetis Therapeutics AB had annual revenue of 57.60M with 154.87% growth.
Revenue (ttm)
67.90M
Revenue Growth
+121.17%
P/S Ratio
22.92
Revenue / Employee
1.74M
Employees
28
Market Cap
1.92B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 57.60M | 35.00M | 154.87% |
Dec 31, 2022 | 22.60M | -15.60M | -40.84% |
Dec 31, 2021 | 38.20M | -2.46M | -6.05% |
Dec 31, 2020 | 40.66M | -41.90M | -50.75% |
Dec 31, 2019 | 82.56M | 54.35M | 192.66% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca PLC | 519.35B |
Swedish Orphan Biovitrum AB (publ) | 25.44B |
Sectra AB (publ) | 3.17B |
Getinge AB (publ) | 33.59B |
Camurus AB (publ) | 1.69B |
Vitrolife AB (publ) | 3.56B |
Medicover AB (publ) | 22.60B |
Elekta AB (publ) | 18.12B |